Germany’s BioNTech (Nasdaq: BNTX) has announced the appointment of Annemarie Hanekamp (pictured, above) as the company’s new chief commercial officer, succeeding Sean Marett.
Ms Hanekamp - a seasoned pharma executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access - joins from Novartis (NOVN: VX), where she headed global radioligand therapy for the Swiss pharma giant.
"An accomplished leader with a track record of more than a dozen successful product launches"In her new role, Ms Hanekamp will drive and execute BioNTech’s global commercialization strategy, tasked with realizing the firm’s full potential as a vertically integrated biopharmaceutical company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze